[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342874-105":59,"doc-detail-342874-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dynamics-of-clonal-hematopoiesis-under-dna-damaging-treatment-in-patients-with-ovarian-cancer","Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer","","Clonal hematopoiesis (CH) driven by DNA damage response (DDR) mutations occurs in cancer patients and increases the risk of therapy-related myeloid neoplasms (t-MNs). Using error-corrected sequencing of 72 genes across 423 serial blood and plasma samples from 103 relapsed high-grade ovarian cancer patients in the EUDARIO phase II trial, DDR-driven CH appeared in 35% and related to longer prior PARPi exposure. DDR-mutated clones expanded more rapidly during treatment, linking their growth to HSP90i exposure and correlating with DDR-driven origins of t-MNs in cases studied by single-cell DNA sequencing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dynamics-of-clonal-hematopoiesis-under-dna-damaging-treatment-in-patients-with-ovarian-cancer/342874/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dynamics-of-clonal-hematopoiesis-under-dna-damaging-treatment-in-patients-with-ovarian-cancer/342874.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is clonal hematopoiesis (CH) and why is it important in cancer patients?","Question",{"text":112,"@type":113},"CH is the expansion of somatically mutated hematopoietic stem cells. In cancer settings, it increases the risk of therapy-related myeloid neoplasms and other age-related inflammatory conditions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DDR-driven CH assessed in this ovarian cancer study?",{"text":117,"@type":113},"The study analyzed 423 serial whole blood and plasma samples from 103 patients receiving carboplatin, PARPi, and HSP90i. DDR-driven CH detection relied on error-corrected sequencing of 72 genes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which DDR-mutated clones expanded more during treatment, and how were they linked to therapy exposure?",{"text":121,"@type":113},"TP53- and PPM1D-mutated clones showed substantially higher clonal expansion rates than DNMT3A- or TET2-mutated clones. DDR clone expansion correlated with HSP90i exposure across study arms and was partly reduced by germline homologous recombination deficiency-related mutations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342874,1790173561,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","[www.nature.com/leu](www.nature.com/leu Leukemia)[ Leukemia](www.nature.com/leu Leukemia)  \nARTICLE OPEN   \nMYELODYSPLASTIC NEOPLASM  \nDynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer  \nChristopher Maximilian Arends 1,16, Klara Kopp 1,16, Raphael Hablesreiter 1, Natalia Estrada1, Friederike Christen 1, Ute Martha Moll2, Robert Zeillinger3, Wolfgang Daniel Schmitt 4, Jalid Sehouli5,6, Hagen Kulbe5,6, Maximilian Fleischmann7, Isabelle Ray-Coquard8, Alain Zeimet9, Francesco Raspagliesi10, Claudio Zamagni 11, Ignace Vergote 12,13, Domenica Lorusso 14, Nicole Concin9, Lars Bullinger1,15, Elena Ioana Braicu5,6,17 and Frederik Damm 1,15,17 ✉  \n© The Author(s) 2024, corrected publication 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer and is associated with a higher risk of therapy-related myeloid neoplasms (t-MNs) . Here, we analyzed 423 serial whole blood and plasma samples from 103 patients with relapsed high-grade ovarian cancer receiving carboplatin, poly(ADP-ribose) polymerase inhibitor (PARPi) and heat shock protein 90 inhibitor (HSP90i) treatment within the phase II EUDARIO trial using error-corrected sequencing of 72 genes. DDR-driven CH was detected in 35% of patients and was associated with longer duration of prior PARPi treatment. TP53-and PPM1D-mutated clones exhibited substantially higher clonal expansion rates than DNMT3A- or TET2-mutated clones during treatment. Expansion of DDR clones correlated with HSP90i exposure across the three study arms and was partially abrogated by the presence of germline mutations related to homologous recombination deﬁciency. Single-cell DNA sequencing of selected samples revealed clonal exclusivity of DDR mutations, and identiﬁed DDR-mutated clones as the origin of t-MN in two investigated cases. Together, these results provide unique insights into the architecture and the preferential selection of DDRmutated hematopoietic clones under intense DNA-damaging treatment. Speciﬁcally, PARPi and HSP90i therapies pose an |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| independent risk for the expansion of DDR-CH in a dose-dependent manner. |  |  |\n|  | Leukemia (2024) 38:1378–1389; [https://doi.org/10.1038/s41375-024-02253-3](https://doi.org/10.1038/s41375-024-02253-3) |  |\n|  |  |  |\n\nINTRODUCTION  \nClonal hematopoiesis (CH), characterized by the expansion of somatically mutated hematopoietic stem cells, has emerged as a prevalent phenomenon associated with the development of hematologic malignancies [1–4], increased cardiovascular risk [5, 6] and other age-related pro-inﬂammatory conditions [7–11] . While in the unselected aging population somatic mutations in epigenetic regulator genes such as DNMT3A, TET2 and ASXL1 (collectively called DTA mutations) predominate, exposure to cytotoxic treatment, in particular platinum-based treatment, differentially selects for gene mutations affecting the DNA  \ndamage response (DDR) machinery, mainly TP53, PPM1D, ATM and CHEK2 [12] . These clones show increased resistance to DNA damage-induced apoptosis, providing them with a selective advantage under the evolutionary pressure of cytotoxic stress [13–16] . Increasing evidence suggests that cancer patients with pre-existing mutant TP53 clones are at elevated risk for developing therapy-related myeloid neoplasms (t-MNs) [12, 17–23] .  \nIn recent years, poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have revolutionized the therapeutic landscape for patients with ovarian cancer, offering improved treatment outcomes and prolonged progression-free survival [24–29] . PARPi selectively  \n1Department of Hematology, Oncology, and Cancer Immunology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. 2D","cbCaig6UPerDXplN","https://ap.wps.com/l/cbCaig6UPerDXplN","pdf",3318192,12,"English","# Introduction\n## Clonal hematopoiesis and therapy-related myeloid neoplasms\n## DDR pathway mutations under cytotoxic selection\n## PARP inhibitors in ovarian cancer","[{\"question\":\"What is clonal hematopoiesis (CH) and why is it important in cancer patients?\",\"answer\":\"CH is the expansion of somatically mutated hematopoietic stem cells. In cancer settings, it increases the risk of therapy-related myeloid neoplasms and other age-related inflammatory conditions.\"},{\"question\":\"How was DDR-driven CH assessed in this ovarian cancer study?\",\"answer\":\"The study analyzed 423 serial whole blood and plasma samples from 103 patients receiving carboplatin, PARPi, and HSP90i. DDR-driven CH detection relied on error-corrected sequencing of 72 genes.\"},{\"question\":\"Which DDR-mutated clones expanded more during treatment, and how were they linked to therapy exposure?\",\"answer\":\"TP53- and PPM1D-mutated clones showed substantially higher clonal expansion rates than DNMT3A- or TET2-mutated clones. DDR clone expansion correlated with HSP90i exposure across study arms and was partly reduced by germline homologous recombination deficiency-related mutations.\"}]","Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer | PDF",1790048533,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b740f0bf2547c0030ba8178a4bcef88.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11b1103dfea22114f6b462ffbea2e26a.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a7d5a7d97c2554294449c0e7a1e04c7.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/282a682a1e19a8f9fc5a66c7f9b6b560.webp",980,1301]